{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:22:26Z","timestamp":1792081346979,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s11920-008-0056-8","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T12:06:56Z","timestamp":1224072416000},"page":"352-358","source":"Crossref","is-referenced-by-count":24,"title":["Better pharmacotherapy for schizophrenia: What does the future hold?"],"prefix":"10.1007","volume":"10","author":[{"given":"Michael A.","family":"Webber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"56_CR1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.151.10.1409","volume":"151","author":"J.D. Hegarty","year":"1994","unstructured":"Hegarty JD, Baldessarini RJ, Tohen M, et al.: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994, 151:1409\u20131416.","journal-title":"Am J Psychiatry"},{"key":"56_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","volume":"153","author":"M.F. Green","year":"1996","unstructured":"Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153:321\u2013330.","journal-title":"Am J Psychiatry"},{"key":"56_CR3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","volume":"115","author":"S.M. Stahl","year":"2007","unstructured":"Stahl SM, Buckley PF: Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007, 115:4\u201311.","journal-title":"Acta Psychiatr Scand"},{"key":"56_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2004.09.003","volume":"72","author":"W.T. Carpenter","year":"2004","unstructured":"Carpenter WT: Clinical constructs and therapeutic discovery. Schizophr Res 2004, 72:69\u201373.","journal-title":"Schizophr Res"},{"key":"56_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbm122","volume":"34","author":"L. Davidson","year":"2008","unstructured":"Davidson L, Schmutte T, Dinzeo T, et al.: Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr Bull 2008, 34:5\u20138.","journal-title":"Schizophr Bull"},{"key":"56_CR6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/schbul\/sbj044","volume":"32","author":"A.S. Bellack","year":"2006","unstructured":"Bellack AS: Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull 2006, 32:432\u2013442.","journal-title":"Schizophr Bull"},{"key":"56_CR7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/schbul\/sbl072","volume":"33","author":"J.S. Brekke","year":"2007","unstructured":"Brekke JS, Maanse H, Long J, Green MF: How neurocognitive and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull 2007, 33:1247\u20131256.","journal-title":"Schizophr Bull"},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/ajp.2007.164.3.437","volume":"164","author":"S.R. McGurk","year":"2007","unstructured":"McGurk SR, Mueser KT, Feldman K, et al.: Cognitive training for supported employment: 2\u20133 year outcomes of a randomized controlled trial. Am J Psychiatry 2007, 164:437\u2013441.","journal-title":"Am J Psychiatry"},{"key":"56_CR9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.schres.2007.03.002","volume":"93","author":"J.E. Peer","year":"2007","unstructured":"Peer JE, Spaulding WD: Heterogeneity in recovery of psychosocial functioning during psychiatric rehabilitation: an exploratory study using latent growth mixture modeling. Schizophr Res 2007, 93:186\u2013193.","journal-title":"Schizophr Res"},{"key":"56_CR10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"J.P. McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, et al.: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600\u2013610.","journal-title":"Am J Psychiatry"},{"key":"56_CR11","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","volume":"100","author":"C. Sur","year":"2003","unstructured":"Sur C, Mallorga PJ, Wittmann M, et al.: N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 2003, 100:13674\u201313679.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"56_CR12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00406-007-0757-8","volume":"258","author":"S.S. Shim","year":"2008","unstructured":"Shim SS, Hammonds MD, Kee BS: Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008, 258:16\u201327.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"56_CR13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.mp.4001552","volume":"10","author":"D.C. Javitt","year":"2005","unstructured":"Javitt DC, Duncan L, Balla A, Sershen H: Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 2005, 10:276\u2013286.","journal-title":"Mol Psychiatry"},{"key":"56_CR14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","volume":"157","author":"A.E. Evins","year":"2000","unstructured":"Evins AE, Fitzgerald SM, Wine L, et al.: Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000, 157:826\u2013828.","journal-title":"Am J Psychiatry"},{"key":"56_CR15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","volume":"153","author":"D.C. Goff","year":"1996","unstructured":"Goff DC, Tsai G, Manoach DS, et al.: D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996, 153:1628\u20131630.","journal-title":"Am J Psychiatry"},{"key":"56_CR16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","volume":"63","author":"P. Shaw","year":"2006","unstructured":"Shaw P, Sporn A, Gogtay N, et al.: Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006, 63:721\u2013730.","journal-title":"Arch Gen Psychiatry"},{"key":"56_CR17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2007.05.004","volume":"115","author":"J. Lameh","year":"2007","unstructured":"Lameh J, Burstein ES, Taylor E, et al.: Pharmacology of N-desmethylclozapine. Pharmacol Ther 2007, 115:223\u2013231.","journal-title":"Pharmacol Ther"},{"key":"56_CR18","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.npp.1301279","volume":"32","author":"S. Natesan","year":"2007","unstructured":"Natesan S, Reckless GE, Barlow KB, et al.: Evaluation of N-desmethylclozapine as a potential antipsychotic-preclinical studies. Neuropsychopharmacology 2007, 32:1540\u20131549.","journal-title":"Neuropsychopharmacology"},{"key":"56_CR19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","volume":"33","author":"R.W. Buchanan","year":"2007","unstructured":"Buchanan RW: Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007, 33:1013\u20131022.","journal-title":"Schizophr Bull"},{"key":"56_CR20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B. Kirkpatrick","year":"2006","unstructured":"Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214\u2013219.","journal-title":"Schizophr Bull"},{"key":"56_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004850-200103000-00003","volume":"16","author":"M. Berk","year":"2001","unstructured":"Berk M, Ichim C, Brook S: Efficacy of mirtazapine add-on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind, randomized, placebo-controlled study. Int Clin Psychopharmacol 2001, 16:87\u201392.","journal-title":"Int Clin Psychopharmacol"},{"key":"56_CR22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004850-200501000-00006","volume":"20","author":"M.C. Jockers-Scherubl","year":"2005","unstructured":"Jockers-Scherubl MC, Bauer A, Godemann F, et al.: Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2005, 20:27\u201331.","journal-title":"Int Clin Psychopharmacol"},{"key":"56_CR23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/oxfordjournals.schbul.a007026","volume":"29","author":"H. Silver","year":"2003","unstructured":"Silver H, Aharon N, Kaplan A: Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophr Bull 2003, 29:541\u2013546.","journal-title":"Schizophr Bull"},{"key":"56_CR24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.162.2.388","volume":"162","author":"J.A. Bodkin","year":"2005","unstructured":"Bodkin JA, Siris SG, Bermanzohn PC, et al.: Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 2005, 162:388\u2013390.","journal-title":"Am J Psychiatry"},{"key":"56_CR25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hup.902","volume":"23","author":"A. Amiri","year":"2008","unstructured":"Amiri A, Noorbala AA, Nejatisafa AA, et al.: Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol 2008, 23:79\u201386.","journal-title":"Hum Psychopharmacol"},{"key":"56_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","volume":"56","author":"U. Heresco-Levy","year":"1999","unstructured":"Heresco-Levy U, Javitt DC, Ermilov M, et al.: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56:29\u201336.","journal-title":"Arch Gen Psychiatry"},{"key":"56_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(03)00129-4","volume":"66","author":"U. Heresco-Levy","year":"2004","unstructured":"Heresco-Levy U, Javitt DC: Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004, 66:89\u201396.","journal-title":"Schizophr Res"},{"key":"56_CR28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","volume":"164","author":"R.W. Buchanan","year":"2007","unstructured":"Buchanan RW, Javitt DC, Marder SR, et al.: The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164:1593\u20131602.","journal-title":"Am J Psychiatry"},{"key":"56_CR29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"S.T. Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, et al.: Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007, 13:1102\u20131107.","journal-title":"Nat Med"},{"key":"56_CR30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","volume":"72","author":"K.H. Nuechterlein","year":"2004","unstructured":"Nuechterlein KH, Barch DM, Gold JM, et al.: Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004, 72:29\u201339.","journal-title":"Schizophr Res"},{"key":"56_CR31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2004.09.010","volume":"72","author":"S.R. Marder","year":"2004","unstructured":"Marder SR, Fenton W: Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004, 72:5\u20139.","journal-title":"Schizophr Res"},{"key":"56_CR32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.clinpsy.3.022806.091529","volume":"3","author":"M.F. Green","year":"2007","unstructured":"Green MF: Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 2007, 3:159\u2013180.","journal-title":"Annu Rev Clin Psychol"},{"key":"56_CR33","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","volume":"33","author":"J.A. Gray","year":"2007","unstructured":"Gray JA, Roth BL: Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007, 33:1100\u20131119.","journal-title":"Schizophr Bull"},{"key":"56_CR34","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/schbul\/sbm083","volume":"33","author":"R.W. Buchanan","year":"2007","unstructured":"Buchanan RW, Freedman R, Javitt DC, et al.: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007, 33:1120\u20131130.","journal-title":"Schizophr Bull"},{"key":"56_CR35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","volume":"63","author":"A. Olincy","year":"2006","unstructured":"Olincy A, Harris JG, Johnson LL, et al.: Proof-of-concept trial of an alpha-7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006, 63:630\u2013638.","journal-title":"Arch Gen Psychiatry"},{"key":"56_CR36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1301499","volume":"33","author":"R.S. Keefe","year":"2008","unstructured":"Keefe RS, Malhotra AK, Meltzer HY, et al.: Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008, 33:1217\u20131228.","journal-title":"Neuropsychopharmacology"},{"key":"56_CR37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2006.03.037","volume":"85","author":"T. Sharma","year":"2006","unstructured":"Sharma T, Reed C, Aasen I, Kumari V: Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006, 85:73\u201383.","journal-title":"Schizophr Res"},{"key":"56_CR38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.ajp.2007.07050724","volume":"165","author":"R.W. Buchanan","year":"2008","unstructured":"Buchanan RW, Conley RR, Dickinson D, et al.: Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008, 165:82\u201389.","journal-title":"Am J Psychiatry"},{"key":"56_CR39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","volume":"12","author":"T.J. Raedler","year":"2007","unstructured":"Raedler TJ, Bymaster FP, Tandon R, et al.: Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007, 12:232\u2013246.","journal-title":"Mol Psychiatry"},{"key":"56_CR40","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.npp.1300768","volume":"30","author":"Z. Li","year":"2005","unstructured":"Li Z, Huang M, Ichikawa J, et al.: N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005, 30: 1986\u20131995.","journal-title":"Neuropsychopharmacology"},{"key":"56_CR41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2007.03.011","volume":"93","author":"M.S. George","year":"2007","unstructured":"George MS, Molnar CE, Grenesko EL, et al.: A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007, 93:42\u201350.","journal-title":"Schizophr Res"},{"key":"56_CR42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.schres.2007.03.033","volume":"94","author":"Q. Mu","year":"2007","unstructured":"Mu Q, Johnson K, Morgan PS, et al.: A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007, 94:332\u2013341.","journal-title":"Schizophr Res"},{"key":"56_CR43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00004714-200110000-00005","volume":"21","author":"D.C. Goff","year":"2001","unstructured":"Goff DC, Leahy L, Berman I, et al.: A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001, 21:484\u2013487.","journal-title":"J Clin Psychopharmacol"},{"key":"56_CR44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","volume":"33","author":"D.C. Goff","year":"2008","unstructured":"Goff DC, Lamberti JS, Leon AC, et al.: A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33:465\u2013472.","journal-title":"Neuropsychopharmacology"},{"key":"56_CR45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","volume":"44","author":"G. Tsai","year":"1998","unstructured":"Tsai G, Yang P, Chung LC, et al.: D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998, 44:1081\u20131089.","journal-title":"Biol Psychiatry"},{"key":"56_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-3223(98)00287-X","volume":"45","author":"J.I. Friedman","year":"1999","unstructured":"Friedman JI, Temporini H, Davis KL: Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999, 45:1\u201316.","journal-title":"Biol Psychiatry"},{"key":"56_CR47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0920-9964(88)90024-2","volume":"1","author":"R.B. Fields","year":"1988","unstructured":"Fields RB, Van Kammen DP, Peters JL, et al.: Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. Schizophr Res 1988, 1:417\u2013423.","journal-title":"Schizophr Res"},{"key":"56_CR48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0893-133X(01)00249-4","volume":"25","author":"J.I. Friedman","year":"2001","unstructured":"Friedman JI, Adler DN, Temporini H, et al.: Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001, 25:402\u2013409.","journal-title":"Neuropsychopharmacology"},{"key":"56_CR49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"D.A. Lewis","year":"2005","unstructured":"Lewis DA, Hashimoto T, Volk DW: Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6:312\u2013324.","journal-title":"Nat Rev Neurosci"},{"key":"56_CR50","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/archneur.63.10.1372","volume":"63","author":"D.A. Lewis","year":"2006","unstructured":"Lewis DA, Moghaddam B: Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006, 63:1372\u20131376.","journal-title":"Arch Neurol"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-008-0056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-008-0056-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-008-0056-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:41:12Z","timestamp":1559421672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-008-0056-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s11920-008-0056-8","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}